{"id":"https://openalex.org/W2321151730","doi":"https://doi.org/10.1016/j.jval.2013.08.1168","title":"Cost-Effectiveness of Intravitreal Aflibercept in Treating Neovascular Age-Related Macular Degeneration in Sweden","display_name":"Cost-Effectiveness of Intravitreal Aflibercept in Treating Neovascular Age-Related Macular Degeneration in Sweden","publication_year":2013,"publication_date":"2013-10-22","ids":{"openalex":"https://openalex.org/W2321151730","doi":"https://doi.org/10.1016/j.jval.2013.08.1168","mag":"2321151730"},"language":"en","primary_location":{"id":"doi:10.1016/j.jval.2013.08.1168","doi":"https://doi.org/10.1016/j.jval.2013.08.1168","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2013.08.1168","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://doi.org/10.1016/j.jval.2013.08.1168","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001426837","display_name":"Karen M. Clements","orcid":"https://orcid.org/0000-0001-9538-8586","observed_orcids":["https://orcid.org/0000-0001-9538-8586"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K.M. Clements","raw_affiliation_strings":["OptumInsight, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OptumInsight, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053700157","display_name":"Erin Hulbert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124242","display_name":"Optum (United States)","ror":"https://ror.org/0370sjj75","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124242"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E.M. Hulbert","raw_affiliation_strings":["OptumInsight, Eden Prairie, MN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OptumInsight, Eden Prairie, MN, USA","institution_ids":["https://openalex.org/I4210124242"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085124680","display_name":"Hemangi R. Panchmatia","orcid":"https://orcid.org/0009-0007-4501-9484","observed_orcids":["https://orcid.org/0009-0007-4501-9484"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H.R. Panchmatia","raw_affiliation_strings":["OptumInsight, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OptumInsight, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109112511","display_name":"M Eriksson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Eriksson","raw_affiliation_strings":["Bayer AB, Solna, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bayer AB, Solna, Sweden","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037778922","display_name":"KU Wittrup-Jensen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K.U. Wittrup-Jensen","raw_affiliation_strings":["Bayer Pharma AG, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bayer Pharma AG, Berlin, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"J. Nilsson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Nilsson","raw_affiliation_strings":["OptumInsight, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OptumInsight, Stockholm, Sweden","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110212915","display_name":"Milton C. Weinstein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M.C. Weinstein","raw_affiliation_strings":["Harvard School of Public Health, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard School of Public Health, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4000,"currency":"USD","value_usd":4000},"apc_paid":null,"fwci":0.2922,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.65976478,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":"16","issue":"7","first_page":"A506","last_page":"A506"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.8666999936103821,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.8666999936103821,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.12210000306367874,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11438","display_name":"Retinal Imaging and Analysis","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neovascular-age-related-macular-degeneration","display_name":"neovascular age-related macular degeneration","score":0.9179999828338623},{"id":"https://openalex.org/keywords/aflibercept","display_name":"aflibercept","score":0.9319999814033508},{"id":"https://openalex.org/keywords/ranibizumab","display_name":"ranibizumab","score":0.9919999837875366},{"id":"https://openalex.org/keywords/intravitreal-injection","display_name":"intravitreal injection","score":0.8299999833106995},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8240000009536743},{"id":"https://openalex.org/keywords/as-needed-dosing","display_name":"as-needed dosing","score":0.7360000014305115},{"id":"https://openalex.org/keywords/monthly-dosing","display_name":"monthly dosing","score":0.7630000114440918},{"id":"https://openalex.org/keywords/visual-acuity","display_name":"visual acuity","score":0.7960000038146973},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.9760000109672546},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.7059999704360962},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.8230000138282776},{"id":"https://openalex.org/keywords/sweden","display_name":"Sweden","score":0.5360000133514404},{"id":"https://openalex.org/keywords/real-world-data","display_name":"real-world data","score":0.4620000123977661},{"id":"https://openalex.org/keywords/willingness-to-pay-threshold","display_name":"willingness-to-pay threshold","score":0.6679999828338623},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.5360000133514404},{"id":"https://openalex.org/keywords/caregiver-costs","display_name":"caregiver costs","score":0.8040000200271606}],"concepts":[{"id":"https://openalex.org/C2778749236","wikidata":"https://www.wikidata.org/wiki/Q4689286","display_name":"Aflibercept","level":4,"score":0.943839430809021},{"id":"https://openalex.org/C2776403814","wikidata":"https://www.wikidata.org/wiki/Q27429789","display_name":"Macular degeneration","level":2,"score":0.7502131462097168},{"id":"https://openalex.org/C2781100027","wikidata":"https://www.wikidata.org/wiki/Q414270","display_name":"Ranibizumab","level":4,"score":0.7286385297775269},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6454883813858032},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6263748407363892},{"id":"https://openalex.org/C2778257484","wikidata":"https://www.wikidata.org/wiki/Q555066","display_name":"Visual acuity","level":2,"score":0.5697892904281616},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.4596644639968872},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.38252317905426025},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.34254857897758484},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.32833045721054077},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.24564743041992188},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18774941563606262},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.1467946469783783},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.10361242294311523},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jval.2013.08.1168","doi":"https://doi.org/10.1016/j.jval.2013.08.1168","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2013.08.1168","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.jval.2013.08.1168","doi":"https://doi.org/10.1016/j.jval.2013.08.1168","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2013.08.1168","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2318485375","https://openalex.org/W2327476260","https://openalex.org/W2267564976","https://openalex.org/W4243660464","https://openalex.org/W2007909782","https://openalex.org/W2000706675","https://openalex.org/W2181773364","https://openalex.org/W2996163251","https://openalex.org/W2529287259","https://openalex.org/W2984966565"],"abstract_inverted_index":null,"counts_by_year":[{"year":2013,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}